The Deep Vein Thrombosis Market Size is valued at 958.11 Million in 2022 and is predicted to reach 1343.86 Million by the year 2031 at a 4.0 % CAGR during the forecast period for 2023-2031.
Deep vein thrombosis (DVT) is a serious condition that occurs when clots forms in the deep veins of the body. The most dangerous complication of deep vein thrombosis is pulmonary embolism (PE), which can either be asymptomatic or symptomatic. Surgery and pregnancy are the major risk factors associated with deep vein thrombosis. Pregnancy increase hormone level and slower blood flow lead to expansion of uterus and restrict blood flowing back from lower extremities responsible for deep vein thrombosis. Diagnosis of deep vein thrombosis can be made with blood tests such as D-dimer test and imaging tests such as Doppler ultrasound (Duplex), contrast venogram, magnetic resonance imaging (MRI), and computer tomography (CT). There are four types of treatments for deep vein thrombosis include anticoagulant, thrombolytic therapy, IVC filters (Vein Filters), and Stents. Anticoagulant such as unfractionated heparin, low molecular weight heparin (enoxaparin/ Lovenox, dalteparin/Fragmin, or tinzaparin/Innohep, fondaparinux/Arixtra or desirudin/Iprivask), warfarin (Coumadin and Jantoven) are the primary treatment deep vein thrombosis. Thrombolytic therapy such as tissue plasminogen activator agents (tPA) can help to dissolve the blood clot. IVC filters (Vein Filters), also known as “Greenfield filters,” is an umbrella-shaped device that is placed into the large vein, which traps blood clots and prevents deep vein thrombosis and pulmonary embolism. Stents are metal meshwork tubes that are placed into a vein to keep them open.
Market Segmentation
Deep Vein Thrombosis market is segmented into Treatement, Distribution channel and Region. On the basis of Treatment, market is segmented into Clot Busters, Blood Thinners, Inferior Vena Cava Filters, Compression Stockings, Others, on the other side, By Distribution Channel, market is devided into Retail Pharmacy, Hospital Pharmacy, and E-commerce. Regionally, market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Almost one-half million patients are hospitalized for venous thromboembolism (consist of deep vein thrombosis and pulmonary embolism) each year in the United States. In Europe, there are 544,000 venous thromboembolism related death every year. Venous thromboembolism can cause a significant global economic burden. Various diagnostic tests and treatment, prolonged hospital stay, and follow-up care can be extremely costly; for instance estimated medical cost for venous thromboembolism in the U.S is $5-10 billion per year. In U.K venous thromboembolism related cost is 750 million per year. In Australia, venous thromboembolism related costs are estimated at 1.72 billion a year. In June 2017, U.S. FDA (Food and Drug Administration) approved betrixaban (Portola) for the adult with venous thromboembolism (VTE). Pentasaccharides such XARELTO are novel anticoagulants may be preferred over standard therapy due to few drug interactions and no need for frequent monitoring or re-dosing.
Competitive Landscape
Some of The Key Players in The Deep Vein Thrombosis Market:
- Sandoz Inc.
- Teva Pharmaceuticals USA, Inc.
- Sanofi-Aventis U.S. LLC,
- Baxter International Inc.,
- West-Ward Pharmaceuticals,
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Abbott Laboratories,
- Bristol-Myers Squibb Company,
- Pfizer,
- Daiichi Sankyo Co. Ltd.,
- Medtronic plc,
- Johnson & Johnson,
The Deep Vein Thrombosis Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 958.11 Million |
|
Revenue Forecast In 2031 |
USD 1343.86 Million |
|
Growth Rate CAGR |
CAGR of 4.0 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment, By Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Sandoz Inc. Teva Pharmaceuticals USA, Inc. Sanofi-Aventis U.S. LLC, Baxter International Inc., West-Ward Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc. Abbott Laboratories, Bristol-Myers Squibb Company, Pfizer, Daiichi Sankyo Co. Ltd., Medtronic plc, Johnson & Johnson, and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
